Full archive
Pharmacogenomics
Week of 21 July 2026
7 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►CYP2D6 — hydrocodone gives comparable analgesia to oxycodone with much lower opioid exposure in normal metabolisers.
- ►CYP3A5 — synthesis of 68 models: +75 % tacrolimus dose in normal/intermediate metabolisers.
- ►CEP72/CYP3A5 — toward population-specific vincristine dosing in paediatric oncology.
- ►PGx in psychiatry — combinatorial-test-guided antidepressant prescribing modestly improves response in MDD (meta-analysis of RCTs).
Category:
Filters··Min. score
7 articles of 7
Sort
CYP2D6
PubMedHydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.
Postoperative analgesia (joint arthroplasty)
0
Preemptive genotyping
JAMA Netw Open 2026· JulRead
CYP3A5
PubMedA Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics.
Organ transplantation — tacrolimus dosing
0
Dose recommendationCPIC Level A
Clin Pharmacokinet 2026· JulRead
Psychiatry
PubMedClinical effectiveness of pharmacogenomic-guided antidepressant treatment in adult major depressive disorder: systematic review and exploratory platform-aware meta-analysis.
Major depressive disorder — pharmacogenomic-guided antidepressant prescribing
0
PsychiatryPreemptive genotyping
J Psychiatr Res 2026· JulRead
Vincristine-induced peripheral neuropathy (paediatric oncology)
PubMedExtrapolating Vincristine-Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias.
Vincristine-induced peripheral neuropathy (paediatric oncology)
0
Dose recommendation
CPT Pharmacometrics Syst Pharmacol 2026· JulRead
CYP2A6
PubMedImpact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy.
Pancreatic ductal adenocarcinoma — S-1 (tegafur) therapy
0
Ann Surg 2026· JulRead
COMT
PubMedEffect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease.
Parkinson's disease — response to opicapone
0
New interaction
Mov Disord Clin Pract 2026· JulRead
CYP3A4
PubMedA Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor.
PAH / erectile dysfunction — TPN171 drug interactions
0
Dose recommendation
CPT Pharmacometrics Syst Pharmacol 2026· JulRead
References and sources
- CYP2D6 — Postoperative analgesia (joint arthroplasty). JAMA Netw Open 2026. PMID 42446879. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42446879/
- CYP3A5 — Organ transplantation — tacrolimus dosing. Clin Pharmacokinet 2026. PMID 42477302. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42477302/
- Vincristine-induced peripheral neuropathy (paediatric oncology). CPT Pharmacometrics Syst Pharmacol 2026. PMID 42473728. Score 5/10. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70303?af=R
- CYP3A4 — PAH / erectile dysfunction — TPN171 drug interactions. CPT Pharmacometrics Syst Pharmacol 2026. PMID 42471740. Score 4/10. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70298?af=R
- Major depressive disorder — pharmacogenomic-guided antidepressant prescribing. J Psychiatr Res 2026. PMID 42462453. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42462453/
- CYP2A6 — Pancreatic ductal adenocarcinoma — S-1 (tegafur) therapy. Ann Surg 2026. PMID 42475636. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42475636/
- COMT — Parkinson's disease — response to opicapone. Mov Disord Clin Pract 2026. PMID 42473901. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42473901/
